Inhibitors: our greatest challenge. Can we minimize the incidence?

Inhibitors: our greatest challenge. Can we minimize the incidence?

Item
http://www.wikidata.org/entity/Q38070810
A new recombinant factor VIII: from genetics to clinical use.Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia.Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.Key issues in inhibitor management in patients with haemophilia.Non-genetic risk factors and their influence on the management of patients in the clinic.The growing number of hemophilia registries: Quantity vs. quality.Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.New findings on inhibitor development: from registries to clinical studies.TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity.
P2860

Inhibitors: our greatest challenge. Can we minimize the incidence?

Item
http://www.wikidata.org/entity/Q38070810
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Inhibitors: our greatest challenge. Can we minimize the incidence?
@en
type
label
Inhibitors: our greatest challenge. Can we minimize the incidence?
@en
prefLabel
Inhibitors: our greatest challenge. Can we minimize the incidence?
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P478
P577
P698
P356
P1433
P1476
Inhibitors: our greatest challenge. Can we minimize the incidence?
@en
P2093
P2860
P304
P31
P356
P478
P577
P698